Polynucleotide-Based Vaginal Cream for Breast Cancer Patients

A new study conducted by researchers at the University of Naples Federico II has evaluated the efficacy and safety of a polynucleotide-based vaginal cream for treating genitourinary syndrome of menopause (GSM) in breast cancer patients receiving adjuvant therapy. The study found that the cream effectively managed GSM symptoms and was well-tolerated by patients.

Key Takeaways:

• The study enrolled 60 women with breast cancer and GSM, with a mean age of 50.6 ± 7.0 years.
• The participants were treated with a polynucleotide-based vaginal cream for 6 months, and clinical and patient-reported outcomes were assessed at baseline, 1 month, and 6 months.
• The study found significant improvements in the Vaginal Health Index (VHI), Vulvar Assessment Score (VuAS), and Vaginal Assessment Score (VAS) after 6 months of treatment.
• The study concluded that polynucleotide-based vaginal cream is a well-tolerated, non-hormonal option for managing GSM in breast cancer survivors receiving adjuvant therapy.

Statistics:

• Mean VHI increased from 11.9 ± 2.3 to 17.6 ± 2.4 after 6 months of treatment.
• VAS decreased from 6.3 ± 2.0 to 2.3 ± 1.1, while VuAS decreased from 4.7 ± 2.0 to 1.4 ± 1.5 after 6 months.
• 53 out of 60 participants completed the study.

Sources:

• Biostimulation with polynucleotide cream during adjuvant therapy for breast cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2025;315:114754.
• News articles from OBGYN & Reproduction Week, citing the European Journal of Obstetrics & Gynecology and Reproductive Biology.